Spero Therapeutics, Inc. (NASDAQ:SPRO) has been given an average broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

Brokers have set a 1-year consensus price target of $24.00 for the company, according to Zacks. Zacks has also assigned Spero Therapeutics an industry rank of 100 out of 265 based on the ratings given to its competitors.

SPRO has been the subject of several recent analyst reports. Stifel Nicolaus initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They set a “buy” rating and a $26.00 price objective for the company. Cowen initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They set an “outperform” rating for the company. Oppenheimer initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Bank of America initiated coverage on Spero Therapeutics in a report on Monday, November 27th. They set a “neutral” rating for the company.

Spero Therapeutics (NASDAQ:SPRO) opened at $11.44 on Thursday. Spero Therapeutics has a twelve month low of $10.83 and a twelve month high of $15.40.

In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Casper Breum bought 214,285 shares of the business’s stock in a transaction on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, with a total value of $2,999,990.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 649,356 shares of company stock valued at $9,090,984. 13.90% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/spero-therapeutics-inc-spro-given-24-00-consensus-target-price-by-brokerages.html.

Spero Therapeutics Company Profile

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.